MX2023007181A - Compuestos de union a tau. - Google Patents
Compuestos de union a tau.Info
- Publication number
- MX2023007181A MX2023007181A MX2023007181A MX2023007181A MX2023007181A MX 2023007181 A MX2023007181 A MX 2023007181A MX 2023007181 A MX2023007181 A MX 2023007181A MX 2023007181 A MX2023007181 A MX 2023007181A MX 2023007181 A MX2023007181 A MX 2023007181A
- Authority
- MX
- Mexico
- Prior art keywords
- binding compounds
- tau binding
- tau
- tau antibodies
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126024P | 2020-12-16 | 2020-12-16 | |
| PCT/US2021/063551 WO2022132923A1 (en) | 2020-12-16 | 2021-12-15 | Tau binding compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007181A true MX2023007181A (es) | 2023-08-30 |
Family
ID=80112434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007181A MX2023007181A (es) | 2020-12-16 | 2021-12-15 | Compuestos de union a tau. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240059766A1 (https=) |
| EP (1) | EP4263599A1 (https=) |
| JP (1) | JP2023554382A (https=) |
| KR (1) | KR20230157296A (https=) |
| CN (1) | CN117043183A (https=) |
| AU (1) | AU2021403010A1 (https=) |
| CA (1) | CA3205586A1 (https=) |
| IL (1) | IL303638A (https=) |
| MX (1) | MX2023007181A (https=) |
| TW (1) | TW202239765A (https=) |
| WO (1) | WO2022132923A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| CN121773336A (zh) * | 2023-07-20 | 2026-03-31 | 拉亚·蒙托柳加亚 | P-tau免疫测定 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| WO1994013795A1 (en) | 1992-12-14 | 1994-06-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| US6348584B1 (en) | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| EP2319301B1 (en) | 2001-11-30 | 2017-09-06 | Amgen Fremont Inc. | Transgenic animals bearing human Ig lambda light chain genes |
| US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| AU2009298458B2 (en) | 2008-09-30 | 2015-10-08 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
| ES2984483T3 (es) | 2010-03-31 | 2024-10-29 | Ablexis Llc | Ingeniería genética de ratones para la producción de anticuerpos quiméricos |
| MY164376A (en) * | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| KR101981351B1 (ko) * | 2011-10-07 | 2019-09-02 | 에이씨 이뮨 에스.에이. | 타우를 인식하는 포스포특이적 항체 |
| MX350311B (es) | 2011-12-20 | 2017-09-01 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y sus usos. |
| NZ630542A (en) | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| CA2896066C (en) * | 2012-12-21 | 2022-07-12 | Biogen Ma Inc. | Human anti-tau antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| WO2019118906A2 (en) * | 2017-12-14 | 2019-06-20 | University Of Florida Research Foundation | Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein |
| SG11202008098TA (en) * | 2018-03-28 | 2020-10-29 | Axon Neuroscience Se | Antibody-based methods of detecting and treating alzheimer's disease |
-
2021
- 2021-12-15 CN CN202180093407.1A patent/CN117043183A/zh active Pending
- 2021-12-15 JP JP2023536348A patent/JP2023554382A/ja active Pending
- 2021-12-15 WO PCT/US2021/063551 patent/WO2022132923A1/en not_active Ceased
- 2021-12-15 EP EP21844118.6A patent/EP4263599A1/en active Pending
- 2021-12-15 MX MX2023007181A patent/MX2023007181A/es unknown
- 2021-12-15 AU AU2021403010A patent/AU2021403010A1/en not_active Abandoned
- 2021-12-15 CA CA3205586A patent/CA3205586A1/en active Pending
- 2021-12-15 TW TW110147015A patent/TW202239765A/zh unknown
- 2021-12-15 US US18/267,711 patent/US20240059766A1/en active Pending
- 2021-12-15 KR KR1020237024245A patent/KR20230157296A/ko active Pending
- 2021-12-15 IL IL303638A patent/IL303638A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202239765A (zh) | 2022-10-16 |
| US20240059766A1 (en) | 2024-02-22 |
| AU2021403010A9 (en) | 2024-09-26 |
| JP2023554382A (ja) | 2023-12-27 |
| AU2021403010A1 (en) | 2023-07-13 |
| WO2022132923A1 (en) | 2022-06-23 |
| CN117043183A (zh) | 2023-11-10 |
| KR20230157296A (ko) | 2023-11-16 |
| IL303638A (en) | 2023-08-01 |
| CA3205586A1 (en) | 2022-06-23 |
| EP4263599A1 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007181A (es) | Compuestos de union a tau. | |
| MX2022012752A (es) | Compuestos de union a tau. | |
| WO2020176597A9 (en) | N-substituted indoles and other heterocycles for treating brain disorders | |
| MX2023013912A (es) | Metodos para inhibir ras. | |
| PH12022551150A1 (en) | Biparatopic cd73 antibodies | |
| PH12019501929A1 (en) | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same | |
| GEAP202114672A (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| MX2024005811A (es) | Inmunoglobulinas de enlace a tgf?1 y usos de las mismas. | |
| MX2009009636A (es) | Metodos para tratar enfermedades oftalmicas. | |
| MX350355B (es) | Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a. | |
| TW200635608A (en) | Aβ antibodies for use in improving cognition | |
| TW200635607A (en) | Humanized Aβ antibodies for use in improving cognition | |
| EP4691569A3 (en) | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| SG142330A1 (en) | Anti-cd38 human antibodies and uses therefor | |
| BR112022008821A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| MX2018014560A (es) | Metodos para el tratamiento de la miastenia gravis generalizada refractaria. | |
| MX2025003082A (es) | Compuestos de union a tau | |
| PH12022552371A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| PH12020551373A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| MX2023002106A (es) | Anticuerpos fgfr3 y metodos de uso. | |
| MX2021007589A (es) | Anticuerpos anti il-36 y procedimientos de uso de estos. | |
| EP4582446A3 (en) | Methods of treating al amyloidosis | |
| ZA202110285B (en) | Antibodies and methods of use |